Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Deals Medical Device PIC

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

Fineline Cube Sep 1, 2026
Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Fineline Cube Sep 1, 2026
Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Fineline Cube Sep 1, 2026
Company Drug

BMS Breyanzi MZL FDA Approval First CAR-T

Fineline Cube Dec 5, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...

Company Deals

Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient

Fineline Cube Dec 5, 2025

Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Fineline Cube Dec 4, 2025

Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Fineline Cube Dec 4, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced it has received registration approval from China’s National...

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Fineline Cube Dec 4, 2025

Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Fineline Cube Dec 4, 2025

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...

Company Drug

TransThera Tinengotinib Cholangiocarcinoma Priority Review China

Fineline Cube Dec 4, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...

Company Deals R&D

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Fineline Cube Dec 4, 2025

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...

Company Drug

Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss

Fineline Cube Dec 4, 2025

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...

Company Drug

Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma

Fineline Cube Dec 4, 2025

Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...

Company Drug

CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist

Fineline Cube Dec 4, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...

Company Drug

Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications

Fineline Cube Dec 4, 2025

Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...

Company Drug

Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership

Fineline Cube Dec 4, 2025

Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...

Policy / Regulatory

NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary

Fineline Cube Dec 4, 2025

The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...

Company Deals

Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough

Fineline Cube Dec 4, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...

Company Deals

Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization

Fineline Cube Dec 4, 2025

Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...

Company Drug

Hengrui Remimazolam ICU Sedation NMPA Application Accepted

Fineline Cube Dec 3, 2025

Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...

Others

Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children

Fineline Cube Dec 3, 2025

Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...

Company Drug

Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer

Fineline Cube Dec 3, 2025

Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Drug

MSD MK-2214 Fast Track Alzheimer Data Positive

Fineline Cube Dec 3, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) released first‑in‑human data for MK-2214 and MK-1167 in...

Posts pagination

1 … 120 121 122 … 714

Recent updates

  • NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment
  • Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment
  • Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States
  • Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market
  • Laekna Doses First Patient in Phase I Study of LAE118 PI3Kα Inhibitor for Advanced Solid Tumors, Licensed to Vasque Bio for Up to USD 527 Million
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Company Policy / Regulatory

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Company Drug

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Policy / Regulatory

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.